Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
0.9900
-0.0053 (-0.53%)
At close: Apr 1, 2026, 4:00 PM EDT
0.9900
0.00 (0.00%)
After-hours: Apr 1, 2026, 6:30 PM EDT
Actinium Pharmaceuticals Employees
Actinium Pharmaceuticals had 25 employees as of September 30, 2025. The number of employees decreased by 12 or -32.43% compared to the same quarter last year.
Employees
25
Change
-12
Growth
-32.43%
Revenue / Employee
$3,600
Profits / Employee
-$1,355,480
Market Cap
30.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 25 | -12 | -32.43% |
| Jun 30, 2025 | 27 | -10 | -27.03% |
| Mar 31, 2025 | 31 | -18 | -36.73% |
| Dec 31, 2024 | 37 | -12 | -24.49% |
| Sep 30, 2024 | 37 | -12 | -24.49% |
| Dec 31, 2023 | 49 | 0 | - |
| Dec 31, 2022 | 49 | 17 | 53.13% |
| Dec 31, 2021 | 32 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Evaxion | 46 |
| Longeveron | 38 |
| Kyntra Bio | 34 |
| Palatin Technologies | 29 |
| PDS Biotechnology | 24 |
| INmune Bio | 21 |
| BriaCell Therapeutics | 16 |
ATNM News
- 6 weeks ago - BIOEMTECH and NorthStar Medical Radioisotopes Announce Strategic Supply Agreement for Actinium-225 to Support Preclinical Radiopharmaceutical Research - Business Wire
- 3 months ago - Actinium Pharmaceuticals Presents New Preclinical Data Demonstrating Potent Anti-Tumor Activity of ATNM-400 Across Multiple Breast Cancer Subtypes Including Hormone Receptor-Positive, Triple-Negative, and Tamoxifen- and HER2 Therapy-Resistant Breast Cancer Models at SABCS 2025 - PRNewsWire
- 4 months ago - Actinium Pharmaceuticals Announces ATNM-400 Data Demonstrating Potent Efficacy in Triple-Negative Breast Cancer and Ability to Overcome Endocrine and HER2-Targeted Therapy Resistance Being Presented at the San Antonio Breast Cancer Symposium - PRNewsWire
- 4 months ago - The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - Newsfile Corp
- 5 months ago - Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - PRNewsWire
- 5 months ago - Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PRNewsWire
- 6 months ago - Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - PRNewsWire
- 6 months ago - Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - PRNewsWire